ProMIS Neurosciences, Inc. (PMN)
NASDAQ: PMN · Real-Time Price · USD
15.24
+1.94 (14.59%)
Jul 17, 2026, 3:03 PM EDT - Market open
ProMIS Neurosciences Employees
As of December 31, 2025, ProMIS Neurosciences had 11 total employees, including 10 full-time and 1 part-time employees. The number of employees increased by 3 or 37.50% compared to the previous year.
Employees
11
Change (1Y)
3
Growth (1Y)
37.50%
Revenue / Employee
n/a
Profits / Employee
-$3,692,329
Market Cap
136.67M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 11 | 3 | 37.50% | 10 | 1 |
| Dec 31, 2024 | 8 | 1 | 14.29% | 7 | 1 |
| Dec 31, 2023 | 7 | 0 | - | 6 | 1 |
| Dec 31, 2022 | 7 | 1 | 16.67% | 6 | 1 |
| Dec 31, 2021 | 6 | 5 | 500.00% | 5 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Seer, Inc. | 124 |
| Cibus | 118 |
| Fractyl Health | 100 |
| enGene Therapeutics | 82 |
| Pyxis Oncology | 56 |
| Aardvark Therapeutics | 40 |
| Cue Biopharma | 29 |
| Genelux | 26 |
PMN News
- 3 days ago - ProMIS Neurosciences reports amyloid-beta oligomer reduction by PMN310 - TheFly
- 3 days ago - ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026 - GlobeNewsWire
- 9 days ago - ProMIS Neurosciences initiated with a Buy at Roth Capital - TheFly
- 9 days ago - ProMIS Neurosciences initiated with a Buy at Roth Capital - TheFly
- 17 days ago - ProMIS Neurosciences initiated with an Overweight at Cantor Fitzgerald - TheFly
- 6 weeks ago - ProMIS Neurosciences Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - ProMIS Neurosciences to Participate in Upcoming Conferences in June - GlobeNewsWire
- 2 months ago - ProMIS Neurosciences Transcript: AGM 2026 - Transcripts